This is a double-blind, placebo-controlled dose-ranging study of KHK4563 to evaluate the
effect of multiple-dose subcutaneous administration of KHK4563 on the annual asthma
exacerbation rate in adult subjects with uncontrolled, suspected eosinophilic asthma.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.